In vitro effects of interferon-γ and tumor necrosis factor-α on CD34+ bone marrow progenitor cells from aplastic anemia patients and normal donors

Hematology Journal

Volumn 5, Issue 1, 2004, Pages 39-46

  Welsh, Jonathan P ^a   Rutherford, Timothy R ^a   Flynn, Julie ^a   Foukaneli, Theodora ^a   Gordon Smith, Edward C ^a   Gibson, Frances M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aplastic anemia; Apoptosis; CD34+ bone marrow progenitor cells; CD95; IFN gamma; TNF alpha

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; CYCLOSPORIN A; CYTOKINE; FAS ANTIGEN; GAMMA INTERFERON; LYMPHOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL POPULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; INTERMETHOD COMPARISON; LYMPHOCYTE; MALE; MONONUCLEAR CELL; PROTEIN ANALYSIS; SENSITIVITY ANALYSIS; VOLUNTEER;

ANEMIA, APLASTIC; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; ANTIGENS, CD95; APOPTOSIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; CELLS, CULTURED; HEMATOPOIETIC STEM CELLS; HUMANS; INTERFERON TYPE II; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 1342330478     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200340     Document Type: Article

References (33)

1. Gordon-Smith EC, Lewis SM. Aplastic anaemia and other types of bone marrow failure, p68. In: Hoffbrand AV, Lewis SM, Tuddenham EGD (eds). Postgraduate Haematology. Butterworth-Heinemann: 1998.
2. Schrezenmeier H, Bacigalupo A (eds). Aplastic Anaemia: Pathophysiology and Treatment. Cambridge University Press: Cambridge; 2000.
3. Teramura M, Kobayashi S, Iwabe K, Yoshinaga K, Mizoguchi H. Mechanism of action of antithymocyte globulin in the treatment of aplastic anaemia: in vitro evidence for the presence of immunosuppressive mechanism. Br J Haematol 1997; 96: 80.
4. Preville X, Flacher M, LeMauff B, Beauchard S, Davelu P, Tiollier J, Revillard JP. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460.
5. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2000; 37: 3.
6. Takami A, Zeng W, Wang H, Matsuda T, Nakao S. Cytotoxicity against lymphoblastoid cells mediated by a T-cell clone from an aplastic anaemia patient: role of CD59 on target cells. Br J Haematol 1999; 107: 791.
7. Zeng W, Nakao S, Takamatsu H, Yachie A, Takami A, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 1999; 93: 3008.
8. Maciejewski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest 2001; 108: 765.
9. Philpott NJ, Scopes J, Marsh JC, Gordon-Smith EC, Gibson FM. Increased apoptosis in aplastic anemia bone marrow progenitor cells: possible pathophysiologic significance. Exp Hematol 1995; 23: 1642.
10. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol 2000; 111: 1164.
11. Zoumbos NC, Djeu JY, Young NS. Interferon is the suppressor of hematopoiesis generated by stimulated lymphocytes in vitro. J Immunol 1984; 133: 769.
12. Zoumbos NC, Gascon P, Djeu JY, Young NS. Interferon is a mediator of hematopoietic suppression in aplastic anemia in vitro and possibly in vivo. Proc Natl Acad Sci USA 1985; 82: 188.
13. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 1995; 91: 245.
14. Dufour C, Corcione A, Svahn J, Haupt R, Battilana N, Pistoia V. Interferon gamma and tumour necrosis factor alpha are overexpressed in bone marrow T lymphocytes from paediatric patients with aplastic anaemia. Br J Haematol 2001; 115: 1023.
15. Torok-Storb B, Johnson GG, Bowden R, Storb R. Gamma-interferon in aplastic anemia: inability to detect significant levels in sera or demonstrate hematopoietic suppressing activity. Blood 1987; 69: 629.
16. Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB. Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999; 27: 1451.
17. Barcena A, Muench MO, Song KS, Ohkubo T, Harrison MR. Role of CD95/Fas and its ligand in the regulation of the growth of human CD34(+ +)CD38(-) fetal liver cells. Exp Hematol 1999; 27: 1428.
18. Philpott NJ, Turner AJ, Scopes 3, Westby M, Marsh JC, Gordon-Smith EC et al. The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87: 2244.
19. Caux C, Vanbervliet B, Massacrier C, Dezutter-Dambuyant C, Saint-Vis B, Jacquet C et al. CD34 + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF alpha. J Exp Med 1996; 184: 695.
20. Dybedal I, Bryder D, Fossum A, Rusten LS, Jacobsen SE. Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. Blood 2001; 98: 1782.
21. Selleri C, Sato T, Anderson S, Young NS, Maciejewski JP. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death. J Cell Physiol 1995; 165: 538.
22. Stanke K, Hecker S, Kohne E, Debatin K-M. CD95 (Apo1/Fas) mediated apoptosis in cytokine-activated hematopoietic cells. Exp Hematol 1998; 26: 844.
23. Lewis NR, Pallis M, Russell NH. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia. Exp Hematol 2000; 28: 535.
24. Maurillo L, Del Poeta G, Venditti A, Buccisano F, Battaglia A, Santinelli S et al. Quantitative analysis of Fas and bcl-2 expression in hematopoietic precursors. Haematologica 2001; 86: 237.
25. Kim H, Whartenby KA, Georgantas RW, Wingard J, Civin CI. Human CD34(+) hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells 2002; 20: 174.
26. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol 1998; 10: 552.
27. Nagafuji K, Shinbuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood 1995; 86: 883.
28. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205.
29. Luther-Wyrsch A, Nissen C, Wodnar-Filipowicz A. Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anaemia. Br J Haematol 2001; 114: 884.
30. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ. How do cytotoxic lymphocytes kill their targets?. Curr Opin Immunol 1998; 10: 581.
31. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559.
32. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001; 29: 1270.
33. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817.